stockportfolio.pro
Veradermics, Incorporated (MANE)
Healthcare · Biotechnology · NYSE
Veradermics, Incorporated revenue & earnings — last 3 fiscal years
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Gross profit | — | — | — |
| Net income | $-16.49M | $-26.49M | $-70.00M |
| Net margin | — | — | — |
Source: Veradermics, Incorporated SEC filings (10-K).
Explore 3 years of Veradermics, Incorporated financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MANE in your portfolio →
Veradermics, Incorporated financial history by metric
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Veradermics, Incorporated — frequently asked questions
What is Veradermics, Incorporated's revenue?
Veradermics, Incorporated (MANE) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Veradermics, Incorporated profitable?
No — MANE reported a net loss of $-70.00M in fiscal 2025.
What is MANE's P/E ratio?
Veradermics, Incorporated trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Veradermics, Incorporated have?
As of fiscal year 2025, MANE carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Veradermics, Incorporated's market cap?
Veradermics, Incorporated (MANE) has a market capitalization of about $3.99B, based on the latest data in our nightly-refreshed cache.
When does Veradermics, Incorporated's fiscal year end?
MANE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Veradermics, Incorporated's official SEC filings (10-K and 10-Q), covering 3 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.